Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Briquilimab · 2 trials · 2 indications
Incidence and severity of AEs including SAEs, TEAEs and AEIs.
Incidence and severity of treatment emergent AEs/SAEs
| Arm | Type | Description |
|---|---|---|
| Briquilimab | EXPERIMENTAL | Briquilimab via SQ injection |
| Placebo | PLACEBO_COMPARATOR | Placebo Comparator |
| Name | Type | Description |
|---|---|---|
| Briquilimab | DRUG | No additional details needed |
| Placebo | OTHER | Placebo Comparator |
Inclusion Criteria: 1. Provides informed written consent. 2. Previously participated in and completed an eligible Jasper-sponsored clinical trial (in the last 4 months) without any investigational product (IP)-related anaphylactic event 3. Disease specific eligibility: 1. Participants with CSU ...
Briquilimab is an investigational small molecule being studied for the treatment of Chronic Spontaneous Urticaria (CSU), a condition characterized by recurrent hives without an identifiable trigger. It is currently in Phase 1 clinical development, with trials evaluating its safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity in adult patients with CSU.
Briquilimab targets KIT, a receptor tyrosine kinase involved in mast cell growth and function. As a KIT inhibitor, it is being investigated for its potential to modulate mast cell activity in chronic urticaria. This mechanism is central to its proposed role in treating conditions like Chronic Spontaneous Urticaria, where mast cell dysregulation is a key factor.
Briquilimab is being developed by Jasper Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol JSPR. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with chronic urticaria, including a Phase 1 dose escalation study and a Phase 2 open-label extension study.
Briquilimab is in Phase 1 clinical development for Chronic Spontaneous Urticaria. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is a randomized, double-blind, placebo-controlled dose escalation study, and a Phase 2 open-label extension study is also active to assess long-term safety and clinical activity.
Briquilimab is being studied in two clinical trials. The first is NCT06162728, a Phase 1 dose escalation trial in adults with Chronic Spontaneous Urticaria, with 88 participants in the United States and Germany. The second is NCT06736262, a Phase 2 open-label extension study evaluating long-term safety and activity in participants from Jasper-sponsored chronic urticaria trials.
Briquilimab is also known by the ChEMBL identifier CHEMBL5095110, which is a database entry for the compound. No other alternative names have been reported for this drug in the available information. It is a distinct investigational agent being developed by Jasper Therapeutics for chronic urticaria indications.